COOPER COMPANIES INC
CIK 711404 · Ver en SEC EDGAR ↗
Primera presentación ante la SEC: 3 de noviembre de 2004 · Último: 3 de noviembre de 2004
En esta página
- Biografía Trayectoria profesional y perfil público, cuando estén disponibles.
- Insider en Empresas de las que esta persona es un insider informante.
- Transacciones de información privilegiada Cada acción que esta persona compró o vendió, de las declaraciones del Formulario 4.
- Derivados Opciones y otras tenencias de derivados reportadas por esta persona.
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.
Leer más
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.
History
Parker Montgomery, a lawyer, bought Martin H. Smith Co. in 1958. The company was renamed to Cooper, Tinsley Laboratories, Inc. in 1961. Its name was changed to Cooper Laboratories Inc. in 1967, and entered the contact lens business when it acquired British lens maker GlobalVision in 1972.
In 1980, Cooper Laboratories reorganized into three business groups: CooperVision, CooperCare and CooperBiomedical, with Cooper Medical Devices Corp. added as a fourth group one year later.
The company was renamed The Cooper Companies in 1987. Three years later, it was further restructured into three business units: CooperVision, CooperSurgical and CooperVision Pharmaceuticals (dissolved in 2003).
Currently, the firm operates as two business units: CooperVision and CooperSurgical. CooperVision serves contact lens wearers and eye care practitioners. Products include a range of daily, two-week and monthly disposable contact lenses, and other spherical, toric and multifocal lenses for astigmatism, nearsightedness and farsightedness, and presbyopia.
CooperSurgical is the medical device and fertility and genomics unit of the companies. It became a business unit in 1990 and its focus includes women's health and fertility. It is headquartered in Trumbull, Connecticut.
Acquisitions
Ocular Sciences Inc. was acquired by CooperVision in 2005.
CooperSurgical acquired AEGEA Medical, a medical manufacturing company in February 2021. A month later, in March, the company acquired Safe Obstetric Systems, and in December 2021, CooperSurgical acquired Generate Life Sciences for $1.6 billion.
In March 2022, CooperSurgical acquired Cook Medical's reproductive health business for $875 million. During that same year the company acquired EnsEyers, a supplier of orthokeratology and scleral contact lenses.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
Insider en
Transacciones de información privilegiada
Cambio de precio frente a la cotización actual, ajustado por división para acciones corporativas desde la presentación, no comparado con índice de referencia, no anualizado, no ponderado por tamaño
No hay operaciones de mercado abierto registradas; se muestran todas las presentaciones.
| Fecha | Ticker | Código | Acciones | Precio | Valor | Poseído después | Δ propio | A/D | vs ahora |
|---|---|---|---|---|---|---|---|---|---|
| 1 de noviembre de 2004 | COO | A | 18 900 | $69,39 | $1 311 471 | 18 900 Directo | — | Adquirido | 336,8% (precio al 2026-08-21) |
P = Compra en mercado abierto · S = Venta · A = Concesión/premio · M = Ejercicio de opción · G = Regalo · F = Retención de impuestos
Las transacciones de información privilegiada no son una recomendación; las ventas a menudo se deben a motivos de liquidez o fiscales.
Posesiones de derivados (Formulario 4 Tabla II)
Opciones, RSUs y valores convertibles reportados en el Formulario 4 Tabla II.
| Fecha | Ticker | Valor | Subyacente | Precio de ejercicio | Vencimiento | Acciones | A/D |
|---|---|---|---|---|---|---|---|
| 1 de noviembre de 2004 | COO | Common Stock | Common Stock (18 900) | $69,39 | 1 de noviembre de 2014 | 18 900 | Adquirido |
El precio de ejercicio/conversión está en blanco cuando no aplica (p. ej., RSUs).